To further understand whether inhibition of the JAK/STAT3 pathway could increase the sensitivity of human ovarian cancer cells to gefitinib, we tested whether gefitinib sensitivity could be enhanced by siRNA-mediated knockdown of JAK or STAT3. Here, STAT3 is linked to ovarian carcinoma.